Shikonin as a therapeutic agent in renal cell carcinoma: insights from TEK-related causal association with glaucoma

Introduction Renal cell carcinoma (RCC) is a lethal malignancy with rising incidence, while glaucoma, a chronic eye disease, shares systemic mechanisms such as oxidative stress and inflammation with cancers. This study aimed to investigate the causal link between glaucoma and RCC and explore molecular intersections to identify novel therapeutic targets. Methods A two-step Mendelian randomization (MR) analysis using genetic data from the NHGRI-EBI GWAS Catalog and FinnGen database was performed, supplemented by NHANES data. Gene expression analysis (GSE53757, E-MTAB-1980) identified glaucoma-related genes in RCC. Molecular docking and functional assays evaluated shikonin's effects on TEK and AKT/mTOR signaling. Results MR revealed a significant causal relationship between glaucoma and RCC. TEK, a glaucoma-related gene, was downregulated in RCC tissues and correlated with advanced tumor stage and metastasis. Shikonin and acetylshikonin upregulated TEK expression, inhibited RCC cell proliferation/migration, and suppressed AKT/mTOR phosphorylation. Discussion These findings support a role for glaucoma-associated genes in RCC development and progression, highlighting shikonin as a promising therapeutic agent targeting this molecular axis.

• Publication year

  2025

• Venue

  Frontiers in Pharmacology

• Publication date

  2025-07-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3389/fphar.2025.1580704PMID 40808675PMCID 12343566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The extracellular matrix as hallmark of cancer and metastasis: From biomechanics to therapeutic targets

  2024cited by this paper
• Ferroptosis-associated genes and compounds in renal cell carcinoma

  2024cited by this paper
• Imaging in Renal Cell Carcinoma Detection

  2024cited by this paper
• TBK1 is paradoxical in tumor development: a focus on the pathway mediating IFN-I expression

  2024cited by this paper
• Trametinib and M17, a novel small molecule inhibitor of AKT, display a synergistic antitumor effect in triple negative breast cancer cells through the AKT/mTOR and MEK/ERK pathways.

  2024cited by this paper
• New Insights in ATP Synthesis as Therapeutic Target in Cancer and Angiogenic Ocular Diseases

  2024cited by this paper
• Targeted inhibition of the PI3K/AKT/mTOR pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer

  2024cited by this paper
• Interaction of immune cells with renal cancer development: Mendelian randomization (MR) study

  2024cited by this paper
• Emerging roles of TBK1 in cancer immunobiology.

  2024cited by this paper
• Genetic changes and testing associated with childhood glaucoma: A systematic review

  2024cited by this paper
• The Role of Complement Dysregulation in Glaucoma

  2024cited by this paper
• Role of TBK1 Inhibition in Targeted Therapy of Cancer.

  2024cited by this paper
• Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor

  2024cited by this paper
• Advances in targeting the extracellular matrix for glaucoma therapy: current updates

  2023cited by this paper
• Reviewing the Regulators of COL1A1

  2023cited by this paper
• Immunobiology and Metabolic Pathways of Renal Cell Carcinoma.

  2023cited by this paper
• Inflammatory Networks in Renal Cell Carcinoma

  2023cited by this paper
• Macrophage-derived SHP-2 inhibits the metastasis of colorectal cancer via Tie2-PI3K signals

  2023cited by this paper
• Activation of Angiopoietin-Tie2 Signaling Protects the Kidney from Ischemic Injury by Modulation of Endothelial-Specific Pathways

  2023cited by this paper
• Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells

  2023cited by this paper
• Signalling pathways and cell death mechanisms in glaucoma: Insights into the molecular pathophysiology.

  2023cited by this paper
• Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab

  2023cited by this paper
• Tie2 Activation via VE-PTP Inhibition With Razuprotafib as an Adjunct to Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

  2022cited by this paper
• Acetylshikonin exerts anti-tumor effects on non-small cell lung cancer through dual inhibition of STAT3 and EGFR.

  2022cited by this paper
• Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway

  2022cited by this paper
• The Pathomechanism, Antioxidant Biomarkers, and Treatment of Oxidative Stress-Related Eye Diseases

  2022cited by this paper
• MYC: a complex problem.

  2022cited by this paper
• Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment.

  2022cited by this paper
• Tumors, tumor therapies, autoimmunity and the eye.

  2021cited by this paper
• The immune‐related biomarker TEK inhibits the development of clear cell renal cell carcinoma (ccRCC) by regulating AKT phosphorylation

  2021cited by this paper
• Oxidative Stress and Hypoxia Modify Mitochondrial Homeostasis During Glaucoma

  2021cited by this paper
• Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma

  2021cited by this paper
• [Biological functions and ubiquitin modification of TBK1 in innate immunity].

  2021cited by this paper
• Adenosine: The common target between cancer immunotherapy and glaucoma in the eye.

  2021cited by this paper
• Juvenile-onset Open-angle Glaucoma - A Clinical and Genetic Update.

  2021cited by this paper
• Shikonin, a naphthalene ingredient: Therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches.

  2021cited by this paper
• Roots of Lithospermum erythrorhizon promotes retinal cell survival in optic nerve crush-induced retinal degeneration.

  2020cited by this paper
• The fibrotic tumor stroma.

  2020cited by this paper
• Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis

  2020cited by this paper
• A Small Molecule Inhibitor of VE-PTP Activates Tie2 in Schlemm's Canal Increasing Outflow Facility and Reducing Intraocular Pressure

  2020cited by this paper
• Inflammation in Glaucoma: From the back to the front of the eye, and beyond.

  2020cited by this paper
• Targeting TANK-binding kinase 1 (TBK1) in cancer

  2020cited by this paper
• Mendelian genes in primary open angle glaucoma.

  2019cited by this paper
• Pharmacological Properties and Derivatives of Shikonin-A Review in Recent Years.

  2019cited by this paper
• Novel fluorescent probes of 10-hydroxyevodiamine: autophagy and apoptosis-inducing anticancer mechanisms

  2018cited by this paper
• The MR-Base platform supports systematic causal inference across the human phenome

  2018cited by this paper
• Reduced AMPK activation and increased HCAR activation drive anti-inflammatory response and neuroprotection in glaucoma

  2018cited by this paper
• Angiopoietins and Tie2 in vascular inflammation

  2017cited by this paper
• MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data

  2017cited by this paper
• Pericyte-expressed Tie2 controls angiogenesis and vessel maturation

  2017cited by this paper
• Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption

  2017cited by this paper
• Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling.

  2017cited by this paper
• Human TBK1: A Gatekeeper of Neuroinflammation.

  2016cited by this paper
• LRP2 Acts as SHH Clearance Receptor to Protect the Retinal Margin from Mitogenic Stimuli.

  2015cited by this paper
• Hypo- and Hypermorphic FOXC1 Mutations in Dominant Glaucoma: Transactivation and Phenotypic Variability

  2015cited by this paper
• Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways.

  2014cited by this paper
• COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA

  2013cited by this paper
• Use of allele scores as instrumental variables for Mendelian randomization

  2013cited by this paper
• Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data

  2013cited by this paper
• Efficient Design for Mendelian Randomization Studies: Subsample and 2-Sample Instrumental Variable Estimators

  2013cited by this paper
• Shikonin, a Chinese plant-derived naphthoquinone, induces apoptosis in hepatocellular carcinoma cells through reactive oxygen species: A potential new treatment for hepatocellular carcinoma.

  2011cited by this paper
• Ensuring the Stability of the Genome: DNA Damage Checkpoints

  2001cited by this paper
• Biological and environmental specimen banking at the Centers for Disease Control and Prevention.

  1997cited by this paper
• Renal cell carcinoma.

  1956cited by this paper

• No citing papers are available for this paper.